Measles Virus Glycoprotein-Based Lentiviral Targeting Vectors That Avoid Neutralizing Antibodies

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Kneissl, Sabrina ^a   Abel, Tobias ^a   Rasbach, Anke ^a   Brynza, Julia ^a   Schneider Schaulies, Jürgen ^b   Buchholz, Christian J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY K71; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ARTICLE; BINDING SITE; CELL STRAIN HEK293; CONTROLLED STUDY; DILUTION; FLOW CYTOMETRY; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MEASLES VIRUS; NONHUMAN; POINT MUTATION; PROTEIN DOMAIN; PSEUDOTYPING; RECEPTOR BINDING; SERODIAGNOSIS; VIRUS ENTRY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HEMAGGLUTININS, VIRAL; HUMANS; LENTIVIRUS; MEASLES VIRUS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; VIRAL FUSION PROTEINS; VIRUS INTERNALIZATION;

EID: 84867370107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046667     Document Type: Article

References (25)

1. Cockrell AS, Kafri T, (2007) Gene delivery by lentivirus vectors. Mol Biotechnol 36: 184-204.
2. Naldini L, (2011) Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
3. Waehler R, Russell SJ, Curiel DT, (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587.
4. Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, et al. (2008) Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
5. Buchholz CJ, Mühlebach MD, Cichutek K, (2009) Lentiviral vectors with measles virus glycoproteins- dream team for gene transfer? Trends Biotechnol 27: 259-265.
6. Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, et al. (2009) Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther 16: 700-705.
7. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, et al. (2010) Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
8. Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, et al. (2011) DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 19: 686-693.
9. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, et al. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
10. de Swart RL, Yuksel S, Osterhaus AD, (2005) Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79: 11547-11551.
11. Liebert UG, Flanagan SG, Löffler S, Baczko K, ter Meulen V, et al. (1994) Antigenic determinants of measles virus hemagglutinin associated with neurovirulence. J Virol 68: 1486-1493.
12. Moeller K, Duffy I, Duprex P, Rima B, Beschorner R, et al. (2001) Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol 75: 7612-7620.
13. Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, et al. (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530-533.
14. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, et al. (2011) Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 7: e1002240.
15. Ertl OT, Wenz DC, Bouche FB, Berbers GA, Muller CP, (2003) Immunodominant domains of the Measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol 148: 2195-2206.
16. Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, et al. (2007) Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A 104: 19535-19540.
17. Levy C, Amirache F, Costa C, Frecha C, Muller CP, et al. (2012) Lentiviral Vectors Displaying Modified Measles Virus gp Overcome Pre-existing Immunity in In Vivo-like Transduction of Human T and B Cells. Mol Ther 10.1038/mt.2012.96 [doi].
18. Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, et al. (2008) Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112: 4843-4852.
19. Frecha C, Costa C, Levy C, Negre D, Russell SJ, et al. (2009) Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173-3180.
20. Fournier P, Brons NH, Berbers GA, Wiesmuller KH, Fleckenstein BT, et al. (1997) Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. J Gen Virol 78 (Pt 6):: 1295-1302.
21. Ziegler D, Fournier P, Berbers GA, Steuer H, Wiesmuller KH, et al. (1996) Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. J Gen Virol 77 (Pt 10):: 2479-2489.
22. Santiago C, Celma ML, Stehle T, Casasnovas JM, (2010) Structure of the measles virus hemagglutinin bound to the CD46 receptor. Nat Struct Mol Biol 17: 124-129.
23. Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, et al. (2012) Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther 10.1038/gt.2011.209 [doi].
24. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D, (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.
25. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.